Sanofi-aventis Lixisenatide improves glycemic control in type 2 diabetic patients
The 12-week, randomised, double-blind, multicenter Phase III study demonstrated that Lixisenatide was safe and well tolerated in patients with type 2 diabetes. The trial result suggested that Lixisenatide
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.